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Introduction
Ovarian cancer is the seventh most common cancer and the eighth leading cause of cancerrelated deaths among women, responsible for approximately 250, 000 new cases and 150,000 deaths each year worldwide 1 . Due to delayed presentation and diagnosis, over 70% of women with ovarian cancer are diagnosed with stage III/IV disease. The standard treatment for stage III/IV diagnoses involves debulking surgery followed by combination chemotherapy with the drugs carboplatin and paclitaxel. Despite an 80% initial response rate, the majority of women exhibit disease relapse and die from recurrent Carboplatin-resistant disease 2 . It is therefore of great importance to investigate mechanisms and markers that predict ovarian cancer resistance to standard chemotherapy regimens, in order to save patients from damaging, ineffective treatments, and determine if alternative regimens and novel drug combinations would be more beneficial.
The chromosome centric human proteome project (C-HPP) aims for the characterisation of the ~20,300 proteins expressed by the protein-coding genome with respect to gene location on each chromosome, cellular distribution, and quantification 3, 4, 5 . Moreover, the C-HPP also plans to map the major classes of post-translational modifications (PTM) for all of the identified proteins in disease related contexts 6 . N(alpha)-terminal acetylation is one of the most common covalent protein modifications to occur in eukaryotes, with ~80% of soluble human proteins predicted to be N-terminally acetylated 7 . N-terminal acetylation is an irreversible process that typically occurs during protein synthesis and involves the transfer of an acetyl group from acetyl coenzyme A to the α-amino group of a protein's first amino acid, as catalysed by N-terminal acetyltransferases (NATs) 8 . The functional changes induced by N-terminal acetylation can be highly variable but can be broadly categorized into subcellular localization, protein interactions and complex formation, protein folding, and perhaps the most well-known, protein degradation with regard to the N-end rule 9, 10, 11 . The N-end rule pathway targets proteins for ubiquitin-mediated degradation based on their N-terminal residue and the PTM status of this residue. These degradation signals are known as Ndegrons.
Initially N-terminal acetylation was shown to block ATP-dependent ubiquitin-mediated degradation 12 , however it has also been shown to promote sequence specific protein degradation 13 . In eukaryotes there are two N-end rule pathways that form part of the ubiquitin system that target the majority of cellular proteins for degradation; the Ac/N-end and the Arg/N-end rule pathways. In the Ac/N-end rule pathway, proteins containing Nterminally acetylated residues are targeted for degradation. Conversely, the Arg/N-end rule pathway targets specific un-acetylated N-terminal residues (Arg, Phe, Lys, Leu, His, Tyr, Trp, and Ile) and N-terminal Asn and Gln which have been deaminated and then Arginylated 14 . Un-acetylated N-terminal Met followed by a hydrophobic residue are also targeted for degradation by the Arg/N-end rule pathway 15 . Protein N-terminal acetylation is thought to be relevant to cancer development with NATs acting as tumour suppressors in healthy tissues and oncoproteins in cancerous cells 16 .
The aims of this study were to characterise the N-terminal acetylation profile of the ovarian cancer cell line OVCAR-5 in order to identify novel acetylation sites and help determine if the occurrence of N-terminal acetylation differs in chemoresistant cells and therefore can be used as putative markers for chemotherapeutic resistance in ovarian cancer. In order to comprehensively profile the N-terminal acetylation sites and develop spectral libraries, a novel IEF Sephadex flatbed gel method for peptide fractionation of up to 10 mg was developed and applied prior to nano-LC-ESI-MS/MS. The novel method was first applied to trypsin digested mouse brain lysates to show the technique is capable of separating and improving the coverage of highly complex peptide mixtures. Following this the method was then applied to OVCAR-5 cell lysates, enabling the detection of 344 N-terminally acetylated proteins, 12 of which are previously un-reported. This stands in contrast to the 189 Nterminal acetylation sites detected in the unfractionated OVCAR-5 sample.
To determine if variable N-terminal acetylation may play a role in the development of chemoresistance, the results from the IEF fractionation were searched for N-terminally acetylated proteins present in both the modified and un-modified forms that could be analysed further in non-resistant (parental) and carboplatin resistant (CBPR) OVCAR-5 cells.
The protein peptidyl-prolyl cis-trans isomerase A (PPIA), also known as Cyclophilin A, was identified and selected for further analysis given the protein's potential involvement in chemoresistance 17 and given the protein was detected in both the N-terminally acetylated and un-acetylated forms. PPIA was quantified using data independent acquisition methods in the parental and CBPR OVCAR-5 cells. This revealed a higher ratio of un-acetylated to acetylated N-terminal PPIA in the parental compared to the CBPR cells, and a 4.1-fold increase in PPIA abundance overall in the parental cells relative to CBPR OVCAR-5 cells (P = 0.015). 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
Materials and Methods

Preparation of tryptic peptides from mouse brain samples
Freshly dissected P30 mouse brain was lysed at room temperature under denaturing conditions in 10mL of lysis buffer (8 M urea (Merck, Darmstadt, Germany), 20 mM HEPES (ICN Biochemicals, Ohio, USA), pH 8, complete protease inhibitors (Roche, Basel, Switzerland), 10mM NaF (Sigma-Aldrich, St. Louis, USA), 1mM Na 3 VO 4 (Sigma-Aldrich), 1 mM beta-glycerophosphate (Sigma-Aldrich), 2.5 mM sodium pyrophosphate (SigmaAldrich)) with 6 titrations through an 18G needle (Becton Dickinson, Franklin Lakes, USA), followed by 6 titrations through a 21G needle (Becton Dickinson), followed by 3 x 15 second pulses with a 300W sonicator (Branson, Danbury, USA) at 50% amplitude. Lysates were centrifuged at 20,000 x g for 15 minutes at 20°C to remove insoluble material and protein concentrations were estimated using an EZQ protein assay (Life Technologies, Carlsbad, USA). The samples were reduced with 5 mM DTT (Roche) for 45 min at room temperature and alkylated with 10 mM iodoacetamide (IAA) (GE Healthcare, Little Chalfont, UK)) for 30 minutes at room temperature in the dark. Lysates were then diluted to 2 M urea with 20 mM HEPES, pH 8, and digested overnight at 25°C with trypsin-TPCK (Worthington Biochemicals, Lakewood, USA) at an enzyme to substrate ratio of 1:50. Following digestion, samples were acidified with formic acid (FA) (Sigma-Aldrich) and subsequently desalted using 500 mg C18 Sep-Pak SPE cartridges (Waters, Milford, USA). C18 cartridges were conditioned with 5 mL of 100% Acetonitrile (ACN) (Merck), followed by 5 mL of 50% (v/v) ACN, 0.1% FA, and finally 20 mL of 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich).
Sample was loaded onto the conditioned C18 cartridge, washed with 15 mL of 0.1% TFA, and eluted with 6 mL of 50% ACN, 0.1% FA. Desalted samples were dried to completeness overnight in an Alpha 1-2 freeze drier (Martin Christ, Osterode am Harz, Germany). The peptides were then resuspended in 10% ACN to a concentration of 10mg/mL as estimated by the initial protein amount before digestion.
Peptide fractionation by IEF Sephadex gel flatbed electrophoresis
335 mg of Sephadex G-100 SF (GE Healthcare) was mixed with 3 mL 10% (v/v) Acetonitrile (ACN) (Merck) and rehydrated for 72 hours at room temperature. Subsequently, the required volume of mouse brain tryptic digest for 1 mg or 10 mg peptides (0.1 mL or 1 mL, respectively), 180 µL Pharmalyte 3-10 (GE Healthcare) and 50 µL pI-marker mixture (14) were added. Thereafter, 10% (v/v) ACN (Merck) was added to a total volume of 4.5 mL and mixed carefully, to not introduce air-bubbles, with a 5 mL pipette (Eppendorf, Hamburg, Germany peptides, the vacuum concentration step was omitted and the eluate was directly diluted 1:10 in FA2.
OVCAR-5 sample preparation and IEF fractionation
For fractionation by IEF the OVCAR-5 cells were lysed using a Precellys 24 bead beater.
Briefly, the cells were placed in Precellys bead beating tubes (Bertin Technologies, Montigny-le-Bretonneux, France) in 1% (w/v) SDS (GE Healthcare) and homogenised using a Precellys 24 (Bertin Technologies) at 6,300 revolutions per minute for 3 x 1 minute cycles.
The samples were centrifuged at 20,000 x g for 30 minutes, the supernatant was recovered and DNA was subsequently sheared using a Bioruptor (Diagenode, Seraing, Belgium) set to "high" output for 6 x 30 second cycles with one minute breaks between each cycle.
Sonication was carried out in ice-cold water. Protein concentration was quantified using an EZQ protein assay (Life Technologies). Protein extracts were digested with a modified FASP 
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. Briefly, samples were made up to a volume of 200 µL with 7M urea (Merck), 100mM ammonium bicarbonate (UAmBic) (Merck) and reduced by adding a final volume of DTT to 50 mM (Roche) followed with incubation at 20°C for 1 hour. Vivacon ultrafiltration spin columns (Sartorius Vivacon 500, 10,000 MWCO HY) were pre-rinsed at 14,000 x g for 10 minutes with 100 µL UAmBic to remove traces of glycerine. Samples were loaded into the spin columns and centrifuged at 14,000 x g for 10 minutes. 100 µL of 55 mM IAA (GE Healthcare) in UAmBic was added to the spin columns and incubated in the dark for 20 minutes at 20°C.
Samples were centrifuged at 14,000 x g for 10 minutes and washed with 100 µL of U-AmBic twice, followed by one wash with 100 µL of 50 mM U-AmBic. Samples were digested overnight at 37°C with trypsin gold (Promega, Madison, WI, USA) at an enzyme to substrate ratio of 1:50 in 100 µL of 5 mM U-AmBic. 1 mg tryptic peptides from the OVCAR-5 cells 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 was desalted, dried to completeness, re-suspended in 100 µl 10% (v/v) ACN (Merck), and IEF was carried out as described above until 1,000 Vh were reached. Once separated the sample was collected into 20 fractions and prepared for nano-LC-ESI-MS/MS as described above.
Generation of carboplatin resistant OVCAR-5 cells
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Nano -LC-ESI-MS/MS
Nano-LC-ESI-MS/MS was performed using an Ultimate 3000 RSLC system (Thermo-Fisher to adapt the speed of acquisition depending on the intensity of precursor ions (fixed cycle time), and RT 2 (RealTime Re-Think) to exclude previously selected precursor ions from undergoing re-fragmentation unless the chromatographic peak intensity of the ion has increased by a factor of 5. Singly charged precursor ions were excluded from acquisition.
Collision energy ranged from 23% to 65% as determined by the m/z of the precursor ion.
Nano-LC-ESI-MS/MS data analysis
All spectra collected using data dependent acquisition (DDA) were analysed using the MaxQuant were used with a mass error tolerance of 40 ppm. The variable modifications of oxidation of methionine and N-terminal acetylation and the fixed modification of carbamidomethyl of cysteines were specified, with the digestion enzyme specified as trypsin.
The protein false discovery rate (FDR) and peptide spectrum match FDRs were both set to 1% using a target decoy approach, with a minimum peptide length of 7 amino acids 20 . Only unique and razor peptides were used when reporting protein identifications. For the status of N-acetylation, the neXtProt 21 (02-2016) and PRIDE databases were consulted.
Further data analysis was carried out using R (Version 3.0.1, The R Foundation for Statistical
Computing) 22 and additionally the ggplot2 v1.01 23 package. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 24 partner repository with the dataset identifier PXD003547.
Quantification of PPIA by DIA
Nano-LC was performed as described above on 300 ng of the CBPR and un-treated parental OVCAR-5 cells using an Ultimate 3000 RSLC system coupled to an Impact HD™ QTOF mass spectrometer set to acquire data using Bruker's Middle Band CID™ method. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Figure 1D ). The mean additional sequence coverage obtained by the IEF fractionation was 15% for the 1 mg sample and 10% for the 10 mg sample ( Figure 1E, F) .
Results
Validation of IEF Sephadex gel flatbed electrophoresis method using mouse brain
N-terminal acetylation analysis of the IEF fractionated ovarian cancer cell line OVCAR-5
Following validation of the peptide IEF fractionation, the method was applied to the ovarian cancer cell line OVCAR-5. In total 4,305 unique proteins were identified from the OVCAR-5 cells (protein FDR of 1%) of which 2,067 were exclusively detected in the 1 mg IEF fractionated sample (Supporting Table 1a ), as compared to 2,282 proteins detected in the 1 µg of unfractionated sample (44 exclusively identified) (Supporting Table 1b ). Between the IEF fractionated and un-fractionated analyses there was an overlap of 2,238 proteins were identified for 90% of proteins and a mean additional protein sequence coverage of 9.1%
was gained in the IEF fractionated sample as compared to the un-fractionated sample (Supporting Figure 1) . The chromosomal locations of the corresponding genes for all of the identified proteins (IEF fractionated and unfractionated) are provided in Supporting Figure 2 .
All of the detected proteins had an evidence level of PE1 except for androglobin (Q8NX0), which had an evidence level of PE2. However, only one peptide from this protein was identified and hence it does not meet the strcit HPP criteria for the detection of low evidence level proteins, where a minimum of 2 unique peptides with a length of ≥9 amino acids is required.
The total number of identified N-termini peptides was 446 (acetylated and un-acetylated, Supporting Table 2a and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 previously reported. The acetylation status, initiator methionine presence or cleavage, and sample information for the detected novel N-terminal peptides is summarised in Table 1 .
Of the detected N-terminally acetylated amino acid residues 51.6% were Ala, 23.3% were Met, 18.8% were Ser, 4.2% were Thr, 0.8% were Val, 0.5% were Cys, with Asp, Glu, and
Gly each contributing 0.3%. Details for the detected N-terminally acetylated amino acid residues, un-modified N-terminal amino acid residues, and the following amino acid residues for all detected N-terminal peptides are provided in Supporting Table 3 .
The N-terminus of 7 proteins from the IEF fractioned sample were detected with the initiator methionine present and also in the initiator methionine cleaved form (proteins Q96HQ2, Q14974, P62937, P56385, P49189, P46782, P31939). Only one of these proteins was detected in both forms in the unfractionated OVCAR-5 sample. However, both N-terminal forms (with and without initiator methionine) could be detected for 6 of the 7 proteins in 300 ng of the unfractionated OVCAR-5 sample when analysed by DIA using a spectral library generated from the IEF fractionated sample (Supporting Figure 4) .
Quantification of PPIA in parental and CBPR OVCAR-5 cells
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Discussion
In-line with the C-HPP, one aim of this study was to map novel N-terminal acetylation sites from proteins extracted from the ovarian cancer cell line OVCAR-5. In order to comprehensively characterise the human proteome, sample fractionation and analysis methods that allow for the detection of previously uncharacterised proteins and modifications are required. Isoelectric focusing of proteins using Sephadex as a matrix has been previously described by Radola et al. 26 and Görg et al. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 fractionation is relatively short and can usually be finished within 6 hours, inclusive set-up and sampling time (excluding 72 h passive rehydration time required for the Sephadex gel).
Therefore, this method is an interesting candidate for laboratories that want to establish their own, more comprehensive spectral libraries for data-independent mass spectrometry experiments (e.g. SWATH or middle-band CID), without the acquisition of additional, highly specialized and expensive equipment.
Overall a total of 4,305 unique proteins were identified in the IEF fractionated OVCAR-5
sample as compared to 2,282 proteins in the unfractionated sample (protein FDR of 1%).
From these results 379 proteins were detected as being N-terminally acetylated and 63
proteins were detected as being un-modified at the N-terminus. An interesting study by
Lange et al. 31 profiled the N-terminal acetylation status of the naturally degraded proteome of human erythrocyte cells using the TAILS method 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 The 379 proteins detected as being N-terminally acetylated in the IEF fractionated and PPIA is a peptidyl-prolyl cis-trans isomerase (PPIase), a family of proteins with molecular chaperone functions that also catalyse a rate-limiting protein folding process. PPIA falls directly under the transcriptional control of p53 and HIF1 alpha and has been implicated in a number of cancers with expression levels correlating to malignant transformation 33, 34 .
Expression of PPIA is essential for the conformational maintenance of oncogenes, signaling proteins involved in cell proliferation, anti-apoptotic functions, transcription factors, and cell motility regulatory proteins 17 . The immunosuppressant drug cyclosporine A is known to 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 inhibit PPIA, a drug that has the capacity to sensitise Cisplatin and Carboplatin resistant ovarian tumours 35 . Given PPIA can protect cells against oxidative-stress induced apoptosis 36, 37 it has been hypothesised that cyclosporine A may act to reduce chemoresistance partially via the inhibition of PPIA. A study analysing gene expression prior to and following chemotherapy in ovarian tumour tissues found PPIA expression to be increased 2 fold following treatment, however the result was not significant 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 COFRADIC  41 or TAILS   32 , the data presented implies that our method is capable to cover Nterminally modified peptides in at least a complementary fashion, as indicated by their entries into the neXtProt database Therefore our method is of particular use when establishing spectral libraries for DIA analysis.
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